Электропривод скипового подъемника

В работе был разработан и спроектирован электропривод главного скипового подъёмника доменной печи на основе устройства преобразования тока SIMOREG- К. В ходе проектирования были рассчитаны параметры силовой цепи привода, произведён расчёт регулировочных характеристик преобразователя, параметров оптимальной настройки и логарифмических амплитудно-частотных и фазочастотных характеристик электропривода. Также был произведён расчёт переходных характеристик регулируемого электропривода методом математического моделирования и определены показатели качества, которые полностью удовлетворяют требованиям технического задания.The electric drive of the main skip hoist of the blast furnace was designed and designed on the basis of the SIMOREG-K current conversion device. During the design, the parameters of the drive power circuit were calculated, the converter adjusting characteristics, the optimum tuning parameters and the logarithmic amplitude-frequency and phase-frequency characteristics of the drive were calculated. The calculation of the transient characteristics of the regulated electric drive by the method of mathematical modeling was also carried out, and quality indicators were determined that fully satisfy the requirements of the technical assignment

Исследование свойств медных покрытий, полученных с помощью магнетрона с жидкофазной мишенью

В процессе работы проводились экспериментальные исследования структуры, шероховатости, электрического сопротивления и поверхности покрытий, полученных при разных условиях осаждения Осаждение медных покрытий из жидкой фазы с помощью МРС с испаряемой мишенью позволяет получить высокие скорости осаждения, низкое удельное электрическое сопротивление и хорошую адгезию пленок с подложкой по сравнению с осаждением из твердофазной МРС.In the course of the work, experimental studies of the structure, roughness, electrical resistance, and surface coatings obtained under different deposition conditions The deposition of copper coatings by means of an MSS with an evaporated target allows obtaining high deposition rates, low electrical resistivity, and good adhesion of the films to the substrate as compared to precipitation from the solid-state MSS

Neuromorphic Hardware In The Loop: Training a Deep Spiking Network on the BrainScaleS Wafer-Scale System

Emulating spiking neural networks on analog neuromorphic hardware offers several advantages over simulating them on conventional computers, particularly in terms of speed and energy consumption. However, this usually comes at the cost of reduced control over the dynamics of the emulated networks. In this paper, we demonstrate how iterative training of a hardware-emulated network can compensate for anomalies induced by the analog substrate. We first convert a deep neural network trained in software to a spiking network on the BrainScaleS wafer-scale neuromorphic system, thereby enabling an acceleration factor of 10 000 compared to the biological time domain. This mapping is followed by the in-the-loop training, where in each training step, the network activity is first recorded in hardware and then used to compute the parameter updates in software via backpropagation. An essential finding is that the parameter updates do not have to be precise, but only need to approximately follow the correct gradient, which simplifies the computation of updates. Using this approach, after only several tens of iterations, the spiking network shows an accuracy close to the ideal software-emulated prototype. The presented techniques show that deep spiking networks emulated on analog neuromorphic devices can attain good computational performance despite the inherent variations of the analog substrate.Comment: 8 pages, 10 figures, submitted to IJCNN 201

Plasmodynamic synthesis of product based on aluminum in the oxygen atmosphere of a reactor-chamber

In this paper, the possibility is shown to synthesize oxide aluminum using a high-speed electro discharge plasma jet. The synthesized products were characterized by X-Ray diffractometry and transmission electron microscopy

Pattern representation and recognition with accelerated analog neuromorphic systems

Despite being originally inspired by the central nervous system, artificial neural networks have diverged from their biological archetypes as they have been remodeled to fit particular tasks. In this paper, we review several possibilites to reverse map these architectures to biologically more realistic spiking networks with the aim of emulating them on fast, low-power neuromorphic hardware. Since many of these devices employ analog components, which cannot be perfectly controlled, finding ways to compensate for the resulting effects represents a key challenge. Here, we discuss three different strategies to address this problem: the addition of auxiliary network components for stabilizing activity, the utilization of inherently robust architectures and a training method for hardware-emulated networks that functions without perfect knowledge of the system's dynamics and parameters. For all three scenarios, we corroborate our theoretical considerations with experimental results on accelerated analog neuromorphic platforms.Comment: accepted at ISCAS 201

Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.

Anaplastic large cell lymphoma (ALCL) is a rare, aggressive, non-Hodgkin's lymphoma that is characterized by CD30 expression and disease onset in young patients. About half of ALCL patients bear the t(2;5)(p23;q35) translocation, which results in the formation of the nucleophosmin-anaplastic lymphoma tyrosine kinase (NPM-ALK) fusion protein (ALCL ALK(+)). However, little is known about the molecular features and tumour drivers in ALK-negative ALCL (ALCL ALK(-)), which is characterized by a worse prognosis. We found that ALCL ALK(-), in contrast to ALCL ALK(+), lymphomas display high miR-155 expression. Consistent with this, we observed an inverse correlation between miR-155 promoter methylation and miR-155 expression in ALCL. However, no direct effect of the ALK kinase on miR-155 levels was observed. Ago2 immunoprecipitation revealed miR-155 as the most abundant miRNA, and enrichment of target mRNAs C/EBPβ and SOCS1. To investigate its function, we over-expressed miR-155 in ALCL ALK(+) cell lines and demonstrated reduced levels of C/EBPβ and SOCS1. In murine engraftment models of ALCL ALK(-), we showed that anti-miR-155 mimics are able to reduce tumour growth. This goes hand-in-hand with increased levels of cleaved caspase-3 and high SOCS1 in these tumours, which leads to suppression of STAT3 signalling. Moreover, miR-155 induces IL-22 expression and suppresses the C/EBPβ target IL-8. These data suggest that miR-155 can act as a tumour driver in ALCL ALK(-) and blocking miR-155 could be therapeutically relevant. Original miRNA array data are to be found in the supplementary material (Table S1).This work was supported by the SCRI-LIMCR GmbH, the “Jubiläumsfond der Österreichischen Nationalbank” (grant-no. 14856 to O.M.), R.G. was supported by grant SFB P021 from the Austrian Science Funds (FWF), L.K. was supported by grant FWF, P26011, R.M. was supported by FWF grants SFB F28 and SFB F47. S.D.T. is a Senior Lecturer supported with funding from Leukemia and Lymphoma Research.This is the final version of the article. It first appeared from Wiley via http://dx.doi.org/10.1002/path.453

Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial - study protocol

Introduction: Optic neuritis leads to degeneration of retinal ganglion cells whose axons form the optic nerve. The standard treatment is a methylprednisolone pulse therapy. This treatment slightly shortens the time of recovery but does not prevent neurodegeneration and persistent visual impairment. In a phase II trial performed in preparation of this study, we have shown that erythropoietin protects global retinal nerve fibre layer thickness (RNFLT-G) in acute optic neuritis; however, the preparatory trial was not powered to show effects on visual function. Methods and analysis: Treatment of Optic Neuritis with Erythropoietin (TONE) is a national, randomised, double-blind, placebo-controlled, multicentre trial with two parallel arms. The primary objective is to determine the efficacy of erythropoietin compared to placebo given add-on to methylprednisolone as assessed by measurements of RNFLT-G and low-contrast visual acuity in the affected eye 6 months after randomisation. Inclusion criteria are a first episode of optic neuritis with decreased visual acuity to ≤0.5 (decimal system) and an onset of symptoms within 10 days prior to inclusion. The most important exclusion criteria are history of optic neuritis or multiple sclerosis or any ocular disease (affected or non-affected eye), significant hyperopia, myopia or astigmatism, elevated blood pressure, thrombotic events or malignancy. After randomisation, patients either receive 33 000 international units human recombinant erythropoietin intravenously for 3 consecutive days or placebo (0.9% saline) administered intravenously. With an estimated power of 80%, the calculated sample size is 100 patients. The trial started in September 2014 with a planned recruitment period of 30 months. Ethics and dissemination: TONE has been approved by the Central Ethics Commission in Freiburg (194/14) and the German Federal Institute for Drugs and Medical Devices (61-3910-4039831). It complies with the Declaration of Helsinki, local laws and ICH-GCP. Trial registration number: NCT01962571